NRX Historical Financial Ratios
| NRXP Stock | USD 1.19 0.02 1.65% |
NRX Pharmaceuticals is lately reporting on over 88 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Invested Capital of 0.0 will help investors to properly organize and evaluate NRX Pharmaceuticals financial condition quickly.
NRX |
About NRX Financial Ratios Analysis
NRX PharmaceuticalsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate NRX Pharmaceuticals investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on NRX financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across NRX Pharmaceuticals history.
NRX Pharmaceuticals Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing NRX Pharmaceuticals stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on NRX Pharmaceuticals sales, a figure that is much harder to manipulate than other NRX Pharmaceuticals multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is NRX Pharmaceuticals dividend as a percentage of NRX Pharmaceuticals stock price. NRX Pharmaceuticals dividend yield is a measure of NRX Pharmaceuticals stock productivity, which can be interpreted as interest rate earned on an NRX Pharmaceuticals investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Operating Cash Flow Per Share
A measure of the cash generated from a company's normal business operations per share, indicating how much cash is generated from a company's business operations on a per-share basis.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Current Ratio
A liquidity ratio that measures a company's ability to pay short-term obligations or those due within one year. It compares a firm's current assets to its current liabilities.Most ratios from NRX Pharmaceuticals' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into NRX Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NRX Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. To learn how to invest in NRX Stock, please use our How to Invest in NRX Pharmaceuticals guide.At this time, NRX Pharmaceuticals' Days Of Payables Outstanding is relatively stable compared to the past year.
NRX Pharmaceuticals fundamentals Correlations
Click cells to compare fundamentals
NRX Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
NRX Pharmaceuticals fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Ptb Ratio | 1.83 | (191.04) | 107.79 | 98.53 | (2.97) | (2.82) | |
| Book Value Per Share | 57.98 | (1.28) | 0.44 | 0.11 | (1.55) | (1.47) | |
| Free Cash Flow Yield | (0.0147) | (2.71E-4) | (0.0168) | (0.0545) | (0.62) | (0.59) | |
| Operating Cash Flow Per Share | (1.56) | (0.0661) | (0.8) | (0.6) | (2.86) | (2.72) | |
| Pb Ratio | 1.83 | (191.04) | 107.79 | 98.53 | (2.97) | (2.82) | |
| Free Cash Flow Per Share | (1.56) | (0.0661) | (0.8) | (0.6) | (2.86) | (2.72) | |
| Roic | (1.65E-4) | 0.29 | (4.18) | (2.19) | 10.72 | 11.26 | |
| Net Income Per Share | 0.8 | (0.36) | (1.53) | (0.54) | (3.98) | (3.78) | |
| Cash Per Share | 62.9 | 0.23 | 0.59 | 0.3 | 0.61 | 0.58 | |
| Pocfratio | (68.04) | (3.7K) | (59.48) | (18.36) | (1.61) | (1.69) | |
| Pfcf Ratio | (68.04) | (3.7K) | (59.47) | (18.36) | (1.61) | (1.69) | |
| Income Quality | (1.94) | 0.0437 | 0.41 | 1.0 | 0.72 | 0.75 | |
| Roe | 0.0138 | 0.28 | (3.45) | (4.76) | 2.57 | 2.7 | |
| Ev To Operating Cash Flow | (70.5) | (3.7K) | (58.76) | (18.12) | (1.82) | (1.91) | |
| Pe Ratio | 132.06 | (677.26) | (31.27) | (20.72) | (1.16) | (1.1) | |
| Return On Tangible Assets | 0.0127 | (4.2) | (2.19) | (1.36) | (4.12) | (3.92) | |
| Ev To Free Cash Flow | (70.5) | (3.7K) | (58.75) | (18.12) | (1.82) | (1.91) | |
| Earnings Yield | 0.007572 | (0.001477) | (0.032) | (0.0483) | (0.87) | (0.82) | |
| Net Debt To E B I T D A | (2.74) | 0.0205 | 0.29 | 0.24 | (0.15) | (0.14) | |
| Current Ratio | 0.11 | 0.0635 | 2.74 | 1.56 | 0.36 | 0.34 | |
| Tangible Book Value Per Share | 57.98 | (1.28) | 0.44 | 0.11 | (1.55) | (1.47) | |
| Graham Number | 32.36 | 3.22 | 3.91 | 1.17 | 11.78 | 12.25 | |
| Shareholders Equity Per Share | 57.98 | (1.28) | 0.44 | 0.11 | (1.55) | (1.47) | |
| Debt To Equity | 0.0662 | (0.0182) | 0.0249 | 1.42 | (0.78) | (0.74) | |
| Graham Net Net | 57.84 | (1.11) | 0.33 | 0.025 | (1.91) | (1.81) | |
| Interest Debt Per Share | 3.84 | 0.0249 | 0.0114 | 0.16 | 1.23 | 1.11 | |
| Debt To Assets | 0.0609 | 0.27 | 0.0158 | 0.41 | 1.25 | 1.31 | |
| Enterprise Value Over E B I T D A | (78.36) | (161.66) | (23.81) | (18.13) | (1.31) | (1.25) | |
| Price Earnings Ratio | 132.06 | (677.26) | (31.27) | (20.72) | (1.16) | (1.1) | |
| Price Book Value Ratio | 1.83 | (191.04) | 107.79 | 98.53 | (2.97) | (2.82) | |
| Price Earnings To Growth Ratio | 0.13 | 4.67 | (0.0962) | 0.32 | (0.001814) | (0.001905) | |
| Price To Operating Cash Flows Ratio | (68.04) | (3.7K) | (59.48) | (18.36) | (1.61) | (1.69) |
Pair Trading with NRX Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NRX Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NRX Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with NRX Stock
Moving against NRX Stock
| 0.77 | BMY | Bristol Myers Squibb | PairCorr |
| 0.76 | GILD | Gilead Sciences | PairCorr |
| 0.64 | ESPR | Esperion Therapeutics | PairCorr |
| 0.45 | DNA | Ginkgo Bioworks Holdings | PairCorr |
| 0.44 | FLGC | Flora Growth Corp | PairCorr |
The ability to find closely correlated positions to NRX Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NRX Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NRX Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NRX Pharmaceuticals to buy it.
The correlation of NRX Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NRX Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NRX Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for NRX Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for NRX Stock Analysis
When running NRX Pharmaceuticals' price analysis, check to measure NRX Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NRX Pharmaceuticals is operating at the current time. Most of NRX Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NRX Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NRX Pharmaceuticals' price. Additionally, you may evaluate how the addition of NRX Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.